Apellis Pharmaceuticals Inc (APLS)
47.46
-0.03
(-0.06%)
USD |
NASDAQ |
May 03, 16:00
46.01
-1.45
(-3.06%)
After-Hours: 20:00
Apellis Pharmaceuticals Gross Profit (TTM): 338.08M for Dec. 31, 2023
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 338.08M |
| September 30, 2023 | 231.35M |
| June 30, 2023 | 164.04M |
| March 31, 2023 | 93.69M |
| December 31, 2022 | 69.79M |
| September 30, 2022 | 105.29M |
| Date | Value |
|---|---|
| June 30, 2022 | 90.11M |
| March 31, 2022 | 74.50M |
| December 31, 2021 | 61.36M |
| September 30, 2021 | 231.07M |
| June 30, 2021 | 226.22M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
61.36M
Minimum
Dec 2021
338.08M
Maximum
Dec 2023
153.23M
Average
105.29M
Median
Sep 2022
Gross Profit (TTM) Benchmarks
| Blueprint Medicines Corp | 240.84M |
| Sarepta Therapeutics Inc | 1.237B |
| Alnylam Pharmaceuticals Inc | 1.682B |
| Ionis Pharmaceuticals Inc | 778.51M |
| Madrigal Pharmaceuticals Inc | -- |